Cannabis Law Report

DECEMBER 23, 2021

billion by 2025. However, no single cannabinoid drug has received widespread approval in the treatment of pain. The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals – from 2021-2025 – including Epidiolex, Sativex and Dronabinol.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

Cannabis Law Report

JUNE 8, 2021

Currently, the development of effective drugs based on CBD for the treatment of Alzheimer’s disease, dementia, diabetes, and epilepsy is underway. External use allows the production of creams and cosmetics for skin care, balms for muscles and joints treatment, cosmetics for bathing, hair care products. In 2018, the U.S.

Research and Development 98

Research and Development CBD Environment Supply Chain 98

Cannabis Law Report

SEPTEMBER 10, 2019

Instead, CBD is fast garnering a reputation in the medical world as a potentially soothing treatment for conditions like arthritis, epilepsy , mental stress, or muscle pain, even as for certain forms of cancer.). billion by the end of 2025, according to a report released by Grand View Research, Inc. No Guarantees.

CBD 45

CBD Wellness and Beauty Banking Epilepsy 45

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

SEPTEMBER 13, 2021

Commenting on the size and scope of the market for delaying aging, Dr. Chapman added, “There are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 1 according to a major investment bank.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

FEBRUARY 18, 2020

Researchers predict that the market will be valued at $7 billion by the year 2025. And according to a Nielsen analytical report , the US market of legal marijuana will reach $41 billion in revenue by 2025, meaning that New York will make up close to 17% of the market share. In 2018, the New York legal cannabis market reached $1.8

Marijuana 59

Marijuana Consumption Dispensary Vaping 59

Cannabis Law Report

JULY 15, 2022

Last week, federal Health Minister Greg Hunt announced changes to regulations that would allow for medicinal cannabis exports, capitalising on what the Government estimated would be a $70 billion industry by 2025. But bottlenecks remain to doctors prescribing the controversial treatment. ABC Rural: Jennifer Nichols ).

Medicine 52

Medicine Patients Media Supply Chain 52

Veriheal

JUNE 19, 2025

In practice, hundreds of families still find themselves turning to the black market to obtain life-saving treatment for their children. Another woman of age 30 living with severe epilepsy saw her seizures decline from about 200 per month to around 8 with the administration of illegal full-spectrum products.

Patients 52

Patients Epilepsy Medicine Access 52

Cannabis Law Report

JANUARY 12, 2020

It has approved use of cannabis extracts for treatment of a range of illnesses and conditions, including cancer, epilepsy, Alzheimer’s, Parkinson’s disease and anxiety. billion ($96 billion) by the end of 2025. Read more at [link].

Research and Development 59

Research and Development Marijuana Agriculture Medicine 59

Veriheal

FEBRUARY 11, 2025

This long-anticipated development marks a major shift in Kentuckys stance on cannabis, opening new doors for patients seeking alternative treatments. As of January 1, 2025, the long-awaited official launch of Kentuckys medical cannabis program occurred.

Marijuana 59

Marijuana Dispensary Programs Patients 59

Cannabis Law Report

JANUARY 5, 2022

The issued claims protect the use of MYMD-1 in a method of treatment for the progressive and generalized loss of skeletal muscle mass and strength known as sarcopenia. MYMD-1 also shows promise in pre-clinical studies as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic.

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Treatment 40

Cannabis Law Report

OCTOBER 20, 2019

It is also the first FDA approved drug for the treatment of patients with Dravet syndrome. billion in federal tax revenue between 2017 and 2025. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.” as a Schedule II substance. Schmidlkofer, M. Westwood, and J. xv] [link].

Marijuana 45

Marijuana Pharmaceutical Chronic Pain Research and Development 45

Cannabis Law Report

OCTOBER 17, 2019

Many experts believe it can lead to beneficial treatments, reiterated in a report released by the National Academies of Sciences, Engineering, and Medicine in January 2017. billion in 2025, according to Grandview Research. Both THC and CBD are psychoactive, but unlike THC, CBD does not intoxicate.

Law 40

Law Seed-To-Sale Hemp Recreational 40